Jeremy is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology, with a focus on business development and the management of early stage opportunities. Jeremy holds a PhD in physiology from the University of Canterbury (NZ) and is a Fellow of the Australian Institute of Company Directors (AICD).
He has over thirty years experience in the Australian healthcare market, initially by working with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.
Pamela Munster – Director
Professor Munster is a professor of medicine at the University of California San Francisco, where she is leader of the Developmental Therapeutics Program/Helen Diller Family Comprehensive Cancer Center, Director of The Early Phase Clinical Trials Unit, and coleader of the Center for BRCA Research. In addition to her laboratory research, she is an oncologist whose focus is on epigenetics and developing novel strategies to treat patients with incurable cancers. She serves on multiple local, national, and international committees focused on developing new treatments for cancer. She has authored textbooks and is a frequent lecturer. A native of Switzerland, she leads breast awareness campaigns in the US, UAE, and India.
Pamela holds a M.D. from the University of Bern, Switzerland.
David Fuller – Director
Dr Fuller is a pharmaceutical physician with extensive experience in the clinical development, regulatory approval and commercialization of new therapeutic products. He specialises in the early stage development of oncology therapeutics and has over 30 years international experience in the pharma / biotech sector for companies including Roche, Pfizer, Orphan Medical (US), Genzyme (Holland and UK), Arana Therapeutics and, more recently, Syneos Health (CRO). He has directly led 4 product approvals through the US FDA and EMA.
David holds dual qualifications in Medicine and Pharmacy from the University of Sydney.
Keir Loiacono – Director
Keir has had more than 17 years of success across the life sciences and medical device industries, having held commercial, legal and business roles. He is currently the General Counsel and Head of Business Development at OncoSec Medical (NASDAQ: ONCS) a U.S. based immuno-oncology company. Prior to joining OncoSec, Keir was the head of legal at Advaxis Inc. and had spent several years in private practice as an attorney with the Lerner David law firm. Prior to practicing law, he worked in sales and marketing at OraPharma, Inc., which was later acquired by Johnson & Johnson.
Mr. Loiacono is a licensed U.S. Patent Attorney and holds a bachelor’s degree in Biology (cum laude) from Manhattan College and a Juris Doctorate from the Elisabeth Haub School of Law.
Brand has had a long and successful career in ICT both in Government and Private Industry. Brand is a successful entrepreneur, company director and investor. He founded TOWER Software which was acquired by HP in May of 2008. Brand has a degree in Computer Studies from the University of Canberra, has served as a Councillor of the University of Canberra and is now an Adjunct Professor at the University of Canberra.
Brand has served as a Director of NICTA, the Australian ICT Centre of Excellence, Taggle Systems, SNAPeWallet and MyTaggles Pty Ltds. Brand also served as Chairman of Canberra Business Council and a Councilor of the NSW Business Chamber. He has served as Chairman Australian Institute of Company Directors (AICD) Canberra Division and as a Director on the National Board of AICD. He was awarded the 2011 National Pearcey Medal, for a lifetime contribution to Australian ICT and in 2012 he was inducted as a Member into the Order of Australia.
Nick has an Honours Degree in Computing in Business from The University Huddersfield in the UK, an MBA from the University of South Australia and is a Graduate member of the Australian Institute of Company Directors.
He has a long track record of helping to build and grow early-stage companies, and has been a successful angel investor, business mentor, and CEO of a successful investment fund. Nick is a former Chair of Capital Angels, was a founding member of Sydney Angels. He currently sits on the Board of Entry29 and the GRIFFIN Accelerator.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder at EpiAxis Therapeutics